265 related articles for article (PubMed ID: 22794306)
1. A systematic review of dydrogesterone for the treatment of threatened miscarriage.
Carp H
Gynecol Endocrinol; 2012 Dec; 28(12):983-90. PubMed ID: 22794306
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dydrogesterone for the treatment of recurrent miscarriage.
Carp H
Gynecol Endocrinol; 2015 Jun; 31(6):422-30. PubMed ID: 25765519
[TBL] [Abstract][Full Text] [Related]
3. Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-blind, placebo-controlled trial.
Kuptarak A; Phupong V
J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2333929. PubMed ID: 38570191
[TBL] [Abstract][Full Text] [Related]
4. Dydrogesterone support in threatened miscarriage.
El-Zibdeh MY; Yousef LT
Maturitas; 2009 Dec; 65 Suppl 1():S43-6. PubMed ID: 20007011
[TBL] [Abstract][Full Text] [Related]
5. Dydrogesterone in threatened miscarriage: a Malaysian experience.
Pandian RU
Maturitas; 2009 Dec; 65 Suppl 1():S47-50. PubMed ID: 20005647
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for threatened miscarriage.
Qureshi NS
Maturitas; 2009 Dec; 65 Suppl 1():S35-41. PubMed ID: 19945236
[TBL] [Abstract][Full Text] [Related]
7. The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis.
Lee HJ; Park TC; Kim JH; Norwitz E; Lee B
Biomed Res Int; 2017; 2017():3616875. PubMed ID: 29392134
[TBL] [Abstract][Full Text] [Related]
8. Progestogens in the prevention of miscarriage.
Carp HJ
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):55-62. PubMed ID: 26677905
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial.
Chan DM; Cheung KW; Yung SS; Lee VC; Li RH; Ng EH
Trials; 2016 Aug; 17(1):408. PubMed ID: 27534747
[TBL] [Abstract][Full Text] [Related]
10. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial.
Chan DMK; Cheung KW; Ko JKY; Yung SSF; Lai SF; Lam MT; Ng DYT; Lee VCY; Li RHW; Ng EHY
Hum Reprod; 2021 Feb; 36(3):587-595. PubMed ID: 33331637
[TBL] [Abstract][Full Text] [Related]
11. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis.
Li L; Zhang Y; Tan H; Bai Y; Fang F; Faramand A; Chong W; Hai Y
BJOG; 2020 Aug; 127(9):1055-1063. PubMed ID: 32324957
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of progesterone on threatened miscarriage: Difference in drug types.
Wang XX; Luo Q; Bai WP
J Obstet Gynaecol Res; 2019 Apr; 45(4):794-802. PubMed ID: 30632226
[TBL] [Abstract][Full Text] [Related]
13. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage.
Siew JYS; Allen JC; Hui CYY; Ku CW; Malhotra R; Østbye T; Tan TC
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():319-324. PubMed ID: 30077119
[TBL] [Abstract][Full Text] [Related]
14. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
Barbosa MWP; Valadares NPB; Barbosa ACP; Amaral AS; Iglesias JR; Nastri CO; Martins WP; Nakagawa HM
JBRA Assist Reprod; 2018 Jun; 22(2):148-156. PubMed ID: 29488367
[TBL] [Abstract][Full Text] [Related]
15. Dydrogesterone use in early pregnancy.
Mirza FG; Patki A; Pexman-Fieth C
Gynecol Endocrinol; 2016; 32(2):97-106. PubMed ID: 26800266
[TBL] [Abstract][Full Text] [Related]
16. Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook.
Schindler AE
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):49-53. PubMed ID: 27662647
[TBL] [Abstract][Full Text] [Related]
17. Dydrogesterone in threatened abortion: pregnancy outcome.
Omar MH; Mashita MK; Lim PS; Jamil MA
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):421-5. PubMed ID: 16293412
[TBL] [Abstract][Full Text] [Related]
18. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
[TBL] [Abstract][Full Text] [Related]
19. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion.
Zhao H; He W; Yang Z
Int J Gynaecol Obstet; 2022 Mar; 156(3):383-393. PubMed ID: 33864694
[TBL] [Abstract][Full Text] [Related]
20. Dydrogesterone indications beyond menopausal hormone therapy: an evidence review and woman's journey.
Stute P
Gynecol Endocrinol; 2021 Aug; 37(8):683-688. PubMed ID: 33866898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
